← Back to Clinical Trials
Recruiting Phase 1 NCT05032105

The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

Trial Parameters

Condition Anxiety
Sponsor Ohio State University
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 10
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2024-06-04
Completion 2025-12
Interventions
Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)

Brief Summary

The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain. For this study, the targeted area of the brain is the anterior nucleus of the thalamus. This brain region may cause seizures and may also be involved in anxiety. The study will test if FUSA is safe and tolerated, and if it reduces anxiety and brain response to threat in patients with anxiety receiving the procedure for partial-onset epilepsy that is resistant to medications.

Eligibility Criteria

Inclusion Criteria: * Disabling, medically refractory epilepsy (≥2 anti-epileptic drug failures). * Focal onset seizures with secondary generalization; with or without primary generalized seizures. * Previous seizure work-up within 12 months of enrollment date to include: A. Home EEG or EMU video EEG or intracranial EEG. B. High definition MRI imaging/PET imaging. C. Baseline neuropsychological assessment, which includes the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF). * ≥ 3 seizures/month on average within 3 months of enrollment. * Stable medication (including anti-epileptic and psychotropic/psychoactive medications) dosage for 3 months before enrollment. * Moderate-severe anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A) score \> 17. * Anterior Nucleus (AN) identifiable on MRI (structural T1 and T2 images). * Willing to maintain seizure diary (3 months before \& 3 months after). * Involved care provider. * Written informed consent to par

Related Trials